MBX Biosciences
MBX Biosciences Inc is an American clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders. The company utilizes its proprietary Precision Endocrine Peptide (PEP) platform to engineer long-acting peptide candidates for conditions like hypoparathyroidism and post-bariatric hypoglycemia. Principal revenue is currently driven through development capital raised, research collaboration agreements, and milestone payments ahead of commercial authorization. Core end markets encompass endocrinology specialty clinics, rare disease institutes, and prescription patients in North America and international markets. MBX Biosciences holds an innovative position in the biopharmaceutical sector for targeted long-acting peptide drug engineering. The company is headquartered in Carmel, Indiana, and its common stock trades on the Nasdaq Global Market.
4 of the funds FundTelligence covers report a position in MBX Biosciences.
- Legal name
- MBX Biosciences Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
Funds holding MBX Biosciences
- DNB Bioteknologi — DNB · 0.94 % (full portfolio disclosed, September 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.54 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.16 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)